Bilix
1 known investors
Bilix develops therapeutics using a proprietary PEGylated bilirubin platform (BRIXELLE) aimed at anti-inflammatory and anti-cancer drug applications, as well as contrast agents for cancer diagnostics and theranostics. The company targets intractable inflammatory diseases and cancer through drug delivery and diagnostic products.
BiotechDeep TechHealthtech